"09Cd binding to the MT containing region after FPLC. Both sublines differ in GSH level, which is increased only in SSK-rad, cells, and in cellular platinum content, which is reduced in SSK-cis2 cells compared to the parental SSK cell line. These factors may contribute to cisplatin resistance but are not the main cause responsible for the transient nature of the drug resistance observed.
Our results indicate that transient cisplatin resistance in SSK cells can be induced not only by the drug itself but also by v-irradiation and is based on the same mechanism of increased cellular MT content.
Resistance in cancer therapy usually means chemoresistance following drug treatment. However, resistance can also be induced by irradiation 1990b; Osmak & Perovic, 1989) . Since tumour therapy often includes both sequential or concomitant radio-chemotherapy, it is important to study the mechanisms leading to radiation-induced resistance or cross-resistance.
Most of the in vitro studies on drug and radiation interaction have looked into cross-resistance after drug induction and the results are rather controversial. Findings range from no effect (Wallner & Li, 1987; Eichholtz-Wirth et al., 1993; Mitchell et al., 1988) to cross-resistance (Schwartz et al., 1988; Louie et al., 1985) and even to collateral sensitivity . Lehnert et al. (1989 and 1990 ) discuss the contribution of GSH and its related enzymes to the radiation response in drug resistant human tumour cells. They show that two drug resistant sublines with different underlying mechanisms are both radioresistant and only these sublines are radiosensitised by GSH depletion.
There are only few publications concerned with radiation induced drug resistance. They demonstrate altered responsiveness to different classes of antineoplastic agents, such as the topoisomerase II inhibitor VP-16 , cisplatin (Dempke et al., 1992; Hill et al., 1990c; Osmak & Petrovic, 1989) , the antimetabolic drug methotrexate (Sharma & Schimke, 1989) as well as the development of multi-drugresistance (Mattern et al., 1991; Hill et al., 1990a) .
We have previously described cisplatin resistance in a murine fibrosarcoma cell line (SSK-cis), induced by intermittent low dose cisplatin treatment (Eichholtz-Wirth et al., 1993) . This drug resistance was transient and was characterised mainly by elevated metallothionein content.
In the present study we report on cisplatin resistant SSKrad cells that were isolated after fractionated irradiation without any prior drug treatment. The following experiments were performed to identify the mechanisms underlying this radiation induced drug resistance and to compare them to those after cisplatin induction. The data could help to clarify whether the way of generating resistance determines the operating mechanism of resistance, as suggested by Hill et al. (1990b) .
Materials and methods
Cell lines and induction of resistance Mouse fibrosarcoma cells (SSK) were grown as monolayer culture in Eagle's minimal essential medium (MEM), supplemented with 10% calf serum, 0.01% neomycin, and 0.035% NaHCO3, in a humidified CO2 incubator at pH 7.4 and 37°C. Their mean doubling time was 12 h.
About 106 cells were exposed to fractionated y-irradiation (6 Gy per fraction), using a gamma cell 40 caesium-137 source (AECL-Industria, Canada) at a dose rate of 1.2 Gy min-'. After each fraction the cells were allowed to grow until confluency at which time irradiation was repeated up to a total dose of 90 Gy. Twelve clones, denoted SSK-rad, were isolated. These clones exhibited cisplatin resistance. Clone SSK-rad, was used for all experiments. SSK-rad, cells are more elongated than the parental cells but they didn't differ in cell size. Their colonies exhibit more fascicular growth whereas the SSK colonies rather pile up in the centre.
Induction of cisplatin resistance by drug treatment has been described elsewhere (Eichholtz-Wirth et al., 1992 (Table II) . Protein content is not significantly different in all cell lines, whereas cellular drug content is reduced in SSK-cis2 cells but not in SSK-rad, cells (Table I) .
Since thiols were shown to play an important role for cisplatin detoxification in SSK-cis cells, non-protein and protein thiols were determined in SSK-rad, cells. GSH is increased by a factor of 1.9 in SSK-rad, cells compared to the parental SSK cells but is in the normal range in SSK-cis2 cells (Table I) . When resistance is lost the enhanced total GSH level is not significantly changed. GST is slightly increased in both SSK-rad, and SSK-cis2 cells. For SSK-cis Figure 4 demonstrates the loss of drug resistance between passages number 9 and 13. This loss of drug resistance coincides with an increase in CdCl2 toxicity ( Figure 5 ). Various SSK-rad clones that were isolated and tested had the same characteristics as described above; only the time they retained their cisplatin resistance differed, lasting from only 10 passages (as shown in Figures (Figure 6 ). In this semiquantitative assay, fraction numbers 31 to 33 correspond to the MT region (molecular weight of 6,000-10,000). These fractions contain 27% of the cumulative activity in the SSK-rad, cells and only 11% in the parental SSK cells. In contrast, in the GSH region (fractions 36-38), the "'0Cd activity is not significantly increased in the SSK-rad, cells as compared to the parental cells. As a result of these changes, SSK-rad, cells contain only 17% of the "'9Cd activity in the high molecular weight region but the amount is 30% in the parental SSK cells.
Discussion
In this study we have demonstrated that cisplatin resistance can be induced in murine fibrosarcoma cells in vitro by ionising irradiation without prior drug treatment. This acquired drug resistance is not associated with a decrease in radiosensitivity. The mechanisms leading to transient cisplatin resistance are similar to those described after cisplatin induced resistance (Eichholtz-Wirth et al., 1993) . Both in subclones SSK-rad1 and SSK-cis2, several mechanisms may contribute to cisplatin resistance: however, the main factor correlating with the development and loss of cisplatin resistance is the cellular content of metallothioneins. These enhanced MTs do not confer radiation resistance, although they are suggested to play a role in radiation protection by scavenging hydroxyl and superoxide radicals (Thornalley & Vasak, 1985) . Matsubara et al. (1987) showed that the induction of MTs in mouse liver is a significant factor for radiation protection. Also, Hodgkiss (1990) described higher endogenous levels of protein and non-protein thiols in irradiated cells which might reduce the efficacy of radiation itself. Similar to our findings, he observed that the resistant phenotypes can persist through many cell generations in the absence of selection pressure but eventually revert to the same phenotype as the unirradiated population. This suggests that there is no classical gene mutation. However, he did not correlate the increased thiols to the cytotoxic effect of chemotherapeutic agents. In both of our resistant SSK-rad1 and SSK-cis2 clones, increased MT content also lasts for a limited number of generations and it is associated with transient cisplatin resistance, but not with radioresistance. This is independent of the selection procedure. As hypothesised by Kaina et al. (1990) , MTs are required to be in close proximity to the DNA in order to neutralise free radicals in the nucleus and to be an efficient radical scavenger. These authors conclude, -which may be confirmed by our data -, that MT concentrations in the nucleus are probably insufficient for radiation protection. Our results also correspond to those of Miura and Sasaki (1990) , using mouse squamous carcinoma cells, demonstrating that the MT level does not determine intrinsic radiosensitivity. These authors also confirm that the cytotoxic effect of Cd is correlated to the MT content; however, they did not compare the MT level and the cellular sensitivity to cisplatin. Data of Kelley et al. (1988) also indicate that cells with acquired resistance to cisplatin frequently have an increased MT level and overexpress MT mRNA. There is no evidence for gene amplification, suggesting enhanced rate of gene transcription or increased mRNA stability. Reversal of cisplatin resistance is also accompanied by a decrease in MT content. Comparison of the two differently derived sublines SSKrad1 and SSK-cis2 shows that only SSK-rad1 cells exhibit elevated levels of total GSH content which remain elevated also after loss of drug resistance. Moreover, the importance of MTs relative to GSH content for cisplatin resistance is demonstrated by FPLC: the '09Cd activity was unchanged in the GSH fraction but it was 2.5 times higher in the MT region in SSK-rad1 cells compared to the parental SSK cells.
SSK-cis2 cells differed from SSK-rad, cells by reduced cellular platinum content, which was also unchanged upon loss of cisplatin resistance (Eichholtz-Wirth et al., 1993) .
These factors -increased GSH in SSK-rad, cells and reduced cellular platinum content in SSK-cis2 cells -may contribute to cisplatin resistance in the two sublines, showing that the mechanisms involved in cisplatin resistance are multifactorial. However, the dominating factor that correlates with the transient nature of cisplatin resistance is the elevation of the MTs and this is demonstrated for both sublines. This is also stressed by our data on cross resistance to doxorubicin, melphalan and radiation. Cross-resistance to these agents and radiation is reported mainly in cells with altered Pt-DNA binding, reduced cross-links and elevated GSH levels or GSH-dependent enzymes (Hamilton et al., 1985; Hospers et al., 1988) . Since there is no cross resistance in SSK-cis2 and SSK-rad1 cells, this would also suggest other mechanisms responsible for the acquisition of cisplatin resistance in SSK cells.
Resistance has been demonstrated to be multifactorial not only for drug induced resistance but also for radiation induced cisplatin resistance, as also reported by Dempke et al. (1992) . In their human ovarian cells, resistance was associated mainly with enhanced repair and increased tolerance of DNA damage; cisplatin uptake was decreased and cytotoxicity could be enhanced by verapamil, but not by inhibition of GSH with BSO. In our SSK cells, verapamil has no effect on SSK and SSK-cis2 cells (Eichholtz-Wirth, 1993) , whereas BSO treatment may be used to increase cisplatin toxicity for the sensitive and resistant cells (Eichholtz-Wirth, 1993 ; data for SSK-rad1 cells not shown). DNA repair was not studied in our SSK cells.
Drug resistance after fractionated irradiation was described in a series of publications by the group of Hill et al. (1988 Hill et al. ( -1990b for various cellular systems. These authors propose that the patterns of response to antitumour drugs and the associated mechanisms differ depending on the agent employed to induce resistance. According to our results a similar pattern of resistance may rather develop in one model system, independent of the way how drug resistance was induced. This agrees with data on MTX resistance after radiation in different cells by Sharma and Schimke (1989) .
They suggest that different tumour cell types may have differing propensities for developing MTX resistance by different mechanisms. Moreover, the degree of resistance, which is also supposed to correlate to the way of induction and which is usually enhanced upon increasing treatment doses, is only slightly lower in SSK-rad, cells compared to SSK-cis2 cells and cannot be enhanced either by additional irradiation (SSK-rad cells) or by further drug exposure (SSK-cis2 cells).
In our study as well as in most of the published data cited above cisplatin resistance was generated after high dose fractionated radiation. It remains to be determined now whether this induction of cisplatin resistance is a general phenomenon also after a low total radiation dose as well as lower dose per fraction in vitro and in vivo. These data may have implications for combined modality therapy using sequential or simultaneous drug and radiation treatment.
